Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
The latest analyst work on Evolus keeps the modeled fair value steady at US$14.67 per share, even as several firms reduce their published price targets. Those cuts are tied less to a change in the core valuation inputs and more to how analysts interpret the softer preliminary 2025 net revenue outlook, the 2026 guide, and the scaled back long term narrative. As you read on, you will see how to approach this evolving setup and what to watch as the story continues to develop.
Stay updated as the Fair Value for Evolus shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Evolus.
-
Stifel points to management guidance as a reset that clears the deck, suggesting the updated outlook may give the company room to execute against more achievable targets.
-
Despite pulling back its price target to US$17 from US$20, Stifel highlights that management has, in its view, set the stage for success. Some investors may interpret this as confidence in the long term opportunity.
-
Stifel frames preliminary 2025 net revenues as at the low end of expectations, which can pressure sentiment if investors were positioned for a stronger top line profile.
-
Stifel cites tepid 2026 guidance and a meaningful cut to the prior long term outlook, signaling that previous growth assumptions and valuation frameworks may need to be recalibrated.
-
BTIG and Mizuho have both lowered their published price targets, reflecting a reassessment of risk and reward around Evolus after the updated revenue outlook and guidance.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
We’ve flagged 2 risks for Evolus. See which could impact your investment.
-
Evolus was removed from the S&P Pharmaceuticals Select Industry Index, which can influence which institutional investors hold the stock and may affect trading volumes over time.
-
The company issued 2026 earnings guidance, projecting total net revenues between US$327 million and US$337 million.
-
Management indicates the 2026 revenue range would represent 10% to 13% growth over the prior year, which provides a basis for comparing the current outlook with the recent baseline.
-
Fair value remains modeled at US$14.67 per share.
-
The long term annual revenue growth assumption remains at 15.61%.
-
The projected net profit margin stays at 4.22%.
-
The future P/E assumption remains at 61.15x.
-
The discount rate used in the model is effectively stable at 6.98%.